Partial Liver Segment 2/3 Transplantation Study

Program Status

Recruiting

Phase

Phase 1

Prior Immunotherapy Allowed

No

CRC-directed Trial

Yes

Tags

MSI-H/ MMRd, MSS/ MMRp
Location Location Status
Norway
Oslo University Hospital
Oslo 0424 Oslo
Recruiting

Contacts

Magnus Smedman, MD
Contact
23026600 torha@ous-hf.no

Inclusion Criteria

Inclusion Criteria:

Histologically verified adenocarcinoma in colon/rectum.
Liver metastases, not amenable to liver resection
No signs of extra hepatic metastatic disease or local recurrence according to PET/CT scan within 4 weeks prior to the faculty meeting at the transplant unit, except patients may have 1-3 resectable lung lesions all<15mm.
No signs of extra hepatic metastatic disease on CT thorax/abdomen/pelvis within 4 weeks prior to the faculty meeting at the transplant unit, except patients may have 1-3 resectable lung lesions all10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >75, Bilirubin<2 x upper normal level, ASAT,ALAT<5 x upper normal level, Creatinine 10% the last 6 months
Patient BMI > 30
Previous diagnosed bone or CNS metastatic disease.
Previous diagnosed cancer mammae or malignant melanoma.
Palliative resection of primary CRC tumor.

NCT ID

NCT02215889

Date Trial Added

2014-08-13

Updated Date

2024-02-06